Recent investigations have converged on the intersection of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopamine signaling. While GIP stimulators are commonly employed for treating type 2 T2DM, their unexpected consequences on motivation circuits, specifically mediated by dopaminergic pathways, are attracting significant … Read More